Conflict of Interest Declaration: Nothing to Disclose Presenter: Sophie Lamoureux Title of Presentation: A Comparison of Stereotactic Body Radiotherapy.

Slides:

Advertisements

Similar presentations

Pulmonary Stereotactic Ablative Radiotherapy:

Advertisements

CARBON ION THERAPY FOR SACRAL CHORDOMAS

Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.

10th Annual Lung Cancer Conference Radiation Oncology

Do you know what ’ s in people ’ s head?. Brain tumors 72 male 72 male HPI: presents to E.R. with history of confusion, change of personality, left sided.

Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

The Health Roundtable 1-1b_HRT1215-Session_HEGI_JOHNSON_WESTMEAD_NSW Volumetric Modulated Arc Therapy for Stereotactic Body Radiotherapy in Early Lung.

Radiotherapy Planning for Esophageal Cancers Parag Sanghvi, MD, MSPH 9/12/07 Esophageal Cancer Tumor Board Part 1.

Radiotherapy for Kidney cancer

Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer. First report for inoperable population of a phase II trial by Japan Clinical.

Dosimetric Evaluation of Planning Techniques in Lung SBRT

SURGEONS ROLE AND INVOLVEMENT IN SBRT PROGRAM Stephen R. Hazelrigg, M.D. Professor and Chair, Cardiothoracic Surgery Southern Illinois University, School.

Living Beyond Breast Cancer Liver and Lung Metastases Workshop April 29, 2012 Paul B. Gilman, MDLankenau Medical Center.

Vertebral Fractures After Stereotactic Ablative Radiotherapy of Lung Tumors Todd A. Aguilera MD PhD 1, Nicholas Trakul MD PhD 2, David B. Shultz MD PhD.

INTRODUCTION  The majority of clinical trials addressing outcomes in limited- stage small cell lung cancer (LS-SCLC) following definitive chemoradiotherapy.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.

LUNG CANCER Dr.Mohammadzadeh. Lung cancer is the leading cancer killer in the United States. Every year, it accounts for 30% of all cancer deaths— more.

S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane.

WHAT ARE THE RISK FACTORS FOR LUNG CANCER? SMOKING.

PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.

Using Spacers for Delivery of High Dose Radiation Theodore Hong, MD Director, Gastrointestinal Radiation Oncology Massachusetts General Hospital Associate.

Cardiac events after treatment with high dose radiation therapy +/- chemotherapy for non-small cell lung cancer Linglong Tang, Anwen Liu, Daniel Gomez,

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use Of Angiotensin- Converting Enzyme Inhibitors In Patients Receiving Lung Stereotactic.

Validity of more than 30Gy radiation therapy for long-surviving patients with painful bone metastases E.Katayama 1,2, H.Okada 1, I.Asakawa 2, T.Tamamoto.

S L I D E 0 Elderly Patients Undergoing SBRT for Inoperable Early Stage NSCLC Achieve Similar Outcomes to Younger Patients Brandon R. Mancini, Henry S.

THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.

HIGH DOSE RADIOTHERAPY IN THE TREATMENT OF PLEURAL MESOTHELIOMA AFTER PLEURECTOMY/DECORTICATION OR BIOPSY: LONG TERM FOLLW UP, ACUTE AND LATE TOXICITY.

Title: Stereotactic Ablative Radiotherapy (SABR) can be Safe and Effective for Treatment of Central and Ultra-Central Lung Tumors. Author: Aadel Chaudhuri,

Michael Brada Torino 6 March 2015 Perspectives in lung cancer Stereotactic ablative radiation therapy (SABR) in patients with inoperable NSCLC.

Stereotactic Ablative Body Radiotherapy for Non small cell lung cancer

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

Outcomes of Stereotactic Ablative Radiotherapy (SABR) for a Second Primary Lung Cancer (SPLC): Evidence in Support of Routine CT Surveillance C. J.A. Haasbeek,

Approaching early stage disease

Tumor Location Correlates with Radiation Pneumonitis after Stereotactic Body Radiation Therapy (SBRT) for Primary and Oligometastatic Lesions of the Lung.

Taipei VGH Practice Guidelines: Oncology Guidelines Index Cancer of Lung Version Table of Content StagingStaging, ManuscriptManuscript Taipei Veterans.

A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): results.

Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Charlie Comins 10/11/15. Bristol Experience Treated first patient in Feb 2014 Aim to treat 12 patients in first year Treated 25 patients in first 12 months.

Emily Tanzler, MD Waseet Vance, MD

Understanding Radiation Therapy Lecturer Radiological Science

Comparison Between Definitive Chemoradiotherapy and Esophagectomy in Patients With Clinical Stage I Esophageal Squamous Cell Carcinoma Sachiko Yamamoto MD,

Radiation therapy for Early Stage Prostate Cancer

Signs, Symptoms, Interventions ACKNOWLEDGEMENTS AND CONTACTS

Hypofractionated radiotherapy for breast cancer

Extending intracranial treatment options with Leksell Gamma Knife® Icon™ Key Statements from Customer Perspective by University Medical Centre Mannheim.

Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.

Compassionate People World Class Care

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Colorectal SSG: SABR and Oligometastatic Disease

Prognosis of younger patients in non-small cell lung cancer

Osteosarcoma Jessica Davis.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

CK RS for non-resectable pancreatic tumors

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned Joe Y. Chang, MD, PhD, Andrea Bezjak,

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer David M. Guttmann, MD, MTR, Nandita.

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters John J. Cuaron, MD, Ellen D. Yorke, PhD, Amanda Foster, BA, Meier Hsu, MS,

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program

General strategies of Cancer Treatment and evaluation of Response

Results: Purpose/Objectives: Methods: Conclusions:

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Presentation transcript:

Conflict of Interest Declaration: Nothing to Disclose Presenter: Sophie Lamoureux Title of Presentation: A Comparison of Stereotactic Body Radiotherapy with Hypofractionated Radiotherapy for Early Stage Non-small Cell Lung Cancer: Control Rates from a Regional Cancer Centre I have no financial or personal relationships to disclose

Technologies: - Four Dimensional CT Simulation - Integrated PET planning - Conformal Radiation Therapy - On board Cone Beam CT

45 pts

NECC SABR - 48Gy in 4 fractions - VMAT Planning - SABR Tumor Board - Patient Selection Medically inoperable T1 or T2 <5cm Biopsy proven or suspected NSCLCa

NECC SABR Database Baseline demographics T Stage Size Biopsy results PET results PFT Dosimetry

NECC SABR Database Follow up data – q3mos initially Performance Status Survival / Cause of death Lesional control Regional control Distant control

NECC SABR Database Follow up data – CTCAE 4.02 Chest wall pain Esophagitis Pneumonitis Pulmonary Hemorrhage

Patients - 54 Patients were treated with 4800/ Patients were treated with 5200/ Patients were treated with 6000/ Patients were treated with SABR of which 33 were peripheral lesions treated with 4800/4 Central lesions treated with 6000/8 were not analysed. Metastatic lesions are not included in this analysis.

Hypofractionation Toxicity No Data collected

SABR Toxicity Symptomatic Pneumonitis 0 Pulmonary Hemmorhage0 Symptomatic Chest Wall Pain1 Symptomatic Esophagitis0 33 evaluable patients, Median follow up 245 Days

NECC Hypofractionated Demographics Table 1. Demographics of early stage lung cancer patients treated with hypofractionated RT at the NECC CharacteristicValue No. of patients108 Median age (in years)80 (56-99) Status Alive43.5% Deceased56.5% Gender Female40.7% Male59.3% Median diameter (in cm)2.95 ( ) Dose (in cGy)/fraction 4800/1250.0% 5200/1324.1% 6000/1525.9% PET Scan Yes46.1% No53.9% Bone Scan Yes63.7% No36.3% CT Head Yes63.7% No36.3% MRI Head Yes6.9% No93.1%

Overall Survival (Hypofraction) (days)

Lesional Control (Hypofraction) (days)

Regional Disease (Hypofraction)

Metastatic Disease (Hypofraction) (days)

Regional Disease (Hypofraction) (days)

Metastatic Disease (Hypofraction) (days)

Overall Survival (days)

Lesional Control (days)

Conclusion Radiotherapy for early stage lung cancer has advanced significantly at NECC. As of Feb 2015, over 76 SABR treatments have been delivered and 108 hypofractionated radiotherapy treatments. There is a non-significant trend towards improved lesional control with higher doses of RT with no change in regional control, development of metastatic disease, survival or toxicity.